Achmea Investment Management B.V. Makes New $6.47 Million Investment in PerkinElmer, Inc. (NYSE:PKI)

Achmea Investment Management B.V. bought a new position in shares of PerkinElmer, Inc. (NYSE:PKIGet Rating) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 37,087 shares of the medical research company’s stock, valued at approximately $6,470,000.

A number of other institutional investors and hedge funds have also bought and sold shares of PKI. UMB Bank N A MO purchased a new position in PerkinElmer in the 4th quarter worth about $29,000. HighTower Advisors LLC raised its stake in PerkinElmer by 16.8% during the 4th quarter. HighTower Advisors LLC now owns 6,258 shares of the medical research company’s stock valued at $1,260,000 after acquiring an additional 900 shares during the last quarter. Aviva PLC increased its stake in PerkinElmer by 0.7% in the 4th quarter. Aviva PLC now owns 43,465 shares of the medical research company’s stock valued at $8,739,000 after purchasing an additional 300 shares in the last quarter. TD Asset Management Inc. grew its holdings in PerkinElmer by 3.2% during the 4th quarter. TD Asset Management Inc. now owns 40,314 shares of the medical research company’s stock valued at $8,106,000 after buying an additional 1,251 shares during the last quarter. Finally, Citigroup Inc. raised its position in shares of PerkinElmer by 36.5% in the 4th quarter. Citigroup Inc. now owns 96,544 shares of the medical research company’s stock worth $19,411,000 after buying an additional 25,832 shares during the period. 77.06% of the stock is owned by hedge funds and other institutional investors.

PerkinElmer Trading Up 2.2 %

Shares of NYSE:PKI opened at $141.62 on Friday. The firm has a market cap of $17.88 billion, a price-to-earnings ratio of 26.52, a PEG ratio of 0.38 and a beta of 1.14. PerkinElmer, Inc. has a 12 month low of $130.13 and a 12 month high of $203.16. The company’s fifty day simple moving average is $145.11 and its 200 day simple moving average is $153.15. The company has a quick ratio of 1.42, a current ratio of 2.02 and a debt-to-equity ratio of 0.63.

PerkinElmer (NYSE:PKIGet Rating) last released its earnings results on Monday, August 1st. The medical research company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.31. PerkinElmer had a net margin of 13.21% and a return on equity of 16.68%. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the company earned $2.83 EPS. PerkinElmer’s quarterly revenue was up .1% compared to the same quarter last year. As a group, research analysts forecast that PerkinElmer, Inc. will post 7.83 EPS for the current fiscal year.

PerkinElmer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, October 20th. This represents a $0.28 annualized dividend and a dividend yield of 0.20%. PerkinElmer’s dividend payout ratio is currently 5.24%.

Insider Buying and Selling

In other news, insider Andrew Okun sold 3,173 shares of the firm’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $165.42, for a total transaction of $524,877.66. Following the sale, the insider now owns 6,391 shares of the company’s stock, valued at approximately $1,057,199.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Andrew Okun sold 3,173 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $165.42, for a total transaction of $524,877.66. Following the sale, the insider now directly owns 6,391 shares in the company, valued at approximately $1,057,199.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel R. Tereau sold 5,700 shares of the firm’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $145.14, for a total value of $827,298.00. Following the transaction, the insider now owns 13,380 shares in the company, valued at $1,941,973.20. The disclosure for this sale can be found here. Insiders sold 13,898 shares of company stock valued at $2,083,263 over the last quarter. 0.52% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Credit Suisse Group initiated coverage on PerkinElmer in a research report on Wednesday, August 24th. They issued a “neutral” rating and a $175.00 price objective on the stock. Stifel Nicolaus cut shares of PerkinElmer from a “buy” rating to a “hold” rating and lowered their price target for the company from $190.00 to $170.00 in a report on Thursday, August 18th. Barclays increased their target price on shares of PerkinElmer from $125.00 to $149.00 and gave the stock an “underweight” rating in a report on Tuesday, August 2nd. Bank of America downgraded shares of PerkinElmer from a “buy” rating to a “neutral” rating and set a $178.00 price objective for the company. in a research report on Tuesday, August 2nd. Finally, UBS Group began coverage on shares of PerkinElmer in a research report on Wednesday, July 20th. They issued a “buy” rating and a $160.00 target price for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, PerkinElmer has a consensus rating of “Hold” and a consensus price target of $163.40.

PerkinElmer Company Profile

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Read More

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.